EpiVax Therapeutics, Inc. develops precision cancer immunotherapy solutions. self-described.

EpiVax Therapeutics, Inc.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

S Nikhil Kumar

AbbVie Inc.

Astellas Gene Therapies is a center of excellence dedicated to developing genetic medicines with the potential to deliver transformative value for patients. Their focus is on rare diseases of the eye, CNS, and neuromuscular system, with a commitment to discovering, developing, and delivering a broad portfolio of transformative therapies for patients with genetic diseases around the world.

Astellas Gene Therapies

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Metric
Company Name	EpiVax Therapeutics, Inc.	AbbVie Inc.	Astellas Gene Therapies	AstraZeneca PLC
Symbol		ABBV		AZN
MSH ID	COM:EPIVAXTX	COM:ABBVIE	COM:ASTELLASGENETHERAPIES	COM:ASTRAZENECA
Market	PRIVATE	STOCKS	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare	Healthcare & Health Services	Healthcare
Industry	Biotechnology	Drug Manufacturers - General	Biotechnology	Drug Manufacturers - General
Country	US	US		GB
Stage
Employee Count		50K	251	89.90K
Website	epivaxtx.com	abbvie.com	astellasgenetherapies.com	astrazeneca.com
LinkedIn				astrazeneca
Founders

Metric
Market Cap	296.91B		2.37B
Enterprise Value
Monthly Web Traffic	1.18M	1.22K	758.60K
Web Traffic Growth	0.51	-0.71	-0.13
Valuation
Raised Capital	15B

Metric
Revenue	54.32B	45.81B
Revenue (LTM)
Revenue (NTM)
Gross Profit	45.54B	37.54B
EBITDA	18.10B	13.91B
Operating Income	17.43B	8.19B
Net Income	4.86B	5.96B
EPS	2.75	3.84
Diluted EPS	2.74	3.81
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.72	0.82
Operating Profit Margin	0.27	0.19
EBITDA Margin	0.33	0.30
Net Profit Margin	0.11	0.13
Return on Equity	0.57	0.17
Return on Assets	0.04	0.06
Return on Capital Employed	0.15	0.12

EPIV

COM:EPIVAXTX

EpiVax Therapeutics, Inc.

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	46.58	34.12
P/B Ratio	25.09	5.41
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	6.36	5.51
EV Multiple	17.44	16.93

Metric
Days Sales Outstanding	75.54
Days Payables Outstanding		846.26
Days Inventory Outstanding	102.41	239.45
Operating Cycle	181.71	317.44
Cash Conversion Cycle	179.57	95.22
Asset Turnover	0.40	0.47

Metric
Operating Cash Flow	22.84B	10.35B
Free Cash Flow	22.06B	6.57B
Cash Flow to Debt	0.38	0.36
Operating Cash Flow/Sales	0.42	0.23
Free Cash Flow Yield	0.08	0.03

Metric
Cash & Equivalents	12.81B	5.84B
Accounts Receivable	66M
Inventory	4.10B	5.42B
Goodwill	32.29B	20.05B
Debt to Capitalization	0.91	0.48
Debt to Assets	0.45	0.30
Current Ratio	0.96	0.79
Quick Ratio	0.83	0.70

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.01
R&D to Revenue	0.14	0.23
SG&A to Revenue